Tailored therapy of Helicobacter pylori infectio

Not Applicable

Recruiting

• Conditions: Diseases of the digestive system

• Registration Number: KCT0003563
• Lead Sponsor: Kangdong Sacred Heart Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 25 March 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 660

Inclusion Criteria

Aged 19-85 subjects who underwent upper endoscopy and confirmed H. pylori infection by rapid urease test (CLOtest, Pronto Dry New; Medical Instruments Corp, Herford, Germany).
The clinical diagnosis are as follows;
H. pylori infected gastritis (including atrophic gastritis, family history of gastric cancer),
Peptic ulcer disease,
Gastric Mucosa-Associated Lymphoid Tissue(MALT) lymphoma,
Early gastric cancer or gastric adenoma who underwent endoscopic mucosal dissection

Exclusion Criteria

Patients will be excluded if they had received
H. pylori eradication therapy within 1 year;
antibiotics within 4 weeks;
had a surgery of gastric cancer;
malignant tumors other than gastric cancer within 5 years of enroll;
severe systemic disorder such as end stage renal disease or liver cirrhosis,
hematologic disease,
central nervous system infection, organic neurologic disease,
infectious mononucleosis ;
history of allergic reaction to treatment drug;
current taking a drug of contraindication to treatment drug
pregnancy and lactating women;

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Eradcation rates of Helicobacter pylori in PAM(proton pump inhibitor, amoxicillin, metronidazole) and PBMT(proton pump inhibitor, bismuth, metronidazole, tetracyclin) group

Secondary Outcome Measures

Name	Time	Method
Eradcation rates of Helicobacter pylori in PAC(proton pump inhibitor, amoxicillin, clarithromycin) group